About 4DMT
4DMT is a company based in Emeryville (United States) founded in 2013. It operates as a HealthTech. 4DMT has raised $186.59 million across 6 funding rounds from investors including Pfizer, Mirae Asset and Janus Henderson Investors. The company has 227 employees. 4DMT offers products and services including 4D-150 and 4D-710. 4DMT operates in a competitive market with competitors including Kriya Therapeutics, Rezolute, Aviceda Therapeutics, EyePoint Pharmaceuticals and Molecular Partners, among others.
- Headquarter Emeryville, United States
- Employees 227
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website 4dmoleculartherapeutics.com
- Social LinkedIn
- Legal Name 4D Molecular Therapeutics, Inc.
- Annual Revenue$85.21 M (USD)230194.59as on Dec 31, 2025
- Net Profit-$140.11 M (USD)12.9as on Dec 31, 2025
- EBITDA-$151.92 M (USD)16.13as on Dec 31, 2025
- Total Equity Funding$186.59M (USD)
in 6 rounds
- Latest Funding Round$75M (USD), Series C
Jun 2020
- InvestorsPfizer
& 19 more
- Employee Count227
Products & Services of 4DMT
4DMT offers a comprehensive portfolio of products and services, including 4D-150 and 4D-710.
Gene therapy developed for treating eye diseases effectively.
Gene therapy created for cystic fibrosis treatment solutions.
Funding Insights of 4DMT
4DMT has successfully raised a total of $186.59M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $75 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $186.59M
- Total Rounds 6
- Last Round Series C — $75M
- First Round $7M
(Aug 2015)
- Investors Count 20
All 6 funding rounds of 4DMT with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $75M | Series C | – | Viking Global Investors | |
| Sep 2018 | $90M | Series B | – | Viking Global Investors | |
| Sep 2017 | $3M | Series A | – | – | |
| Jan 2016 | – | Series A | – | – | |
| Oct 2015 | $11.59M | Series A | – | – | – |
| Aug 2015 | $7M | Series A | – | – | – |
20 investors in total: 20 institutional.
Investors in 4DMT
4DMT has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Mirae Asset and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding. | – | lvf.vc | New York, USA | |
Chiesi Ventures is focused on venture capital for rare diseases. | – | chiesiventures.com | Boston, United States | |
VC firm focusing on life science sector | – | pappas-capital.com | Durham, United States | |
Ridgeback Capital is focused on healthcare and life science investments. | – | ridgebackcap.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
- | – | berkeleycatalystfund.com | - | |
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Investments in healthcare startups are managed by Octagon Capital Advisors. | – | octagoninvestments.com | New York, United States |
Investor details for 4DMT
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of 4DMT
4DMT is a publicly listed company on the NASDAQ with ticker symbol FDMT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Dec 2020
- Listed onNASDAQ: FDMT
- Listed entity4D Molecular Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS35104E1001
- Share price$12.70 (+0.87% on the day) · 2026-10-08
- Market capitalisation$701.6M
- EPS (diluted, trailing year)$-2.72
- Volume (last session)970,764
Financials of 4DMT
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $85.2M | -$140.1M | -$151.9M |
| 2024 | $37,000 | -$160.9M | -$181.1M |
| 2023 | $20.7M | -$100.8M | -$107.1M |
| 2022 | $3.1M | -$107.5M | -$106.2M |
| 2021 | $18.0M | -$71.3M | -$68.3M |
Detailed financial statements for 4DMT
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of 4DMT
4 dated milestones of 4DMT across 7 years, from founding to its latest funding, stage changes and deals.
- Founded 4DMT is founded.
- Funding First funding round of $7.0M.
- Funding Latest funding round, Series C, of $75.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of 4DMT
4DMT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Rezolute, Aviceda Therapeutics, EyePoint Pharmaceuticals and Molecular Partners, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| avicedarx.com | 2018 | Cambridge, United States | $254.66M | – | Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas. | |
| eyepointpharma.com | 1987 | Watertown, United States | – | 49 | Small molecule therapeutics for ophthalmic disorders are developed. | |
| molecularpartners.com | 2004 | Zurich, Switzerland | $59.94M | – | Therapeutic solutions for diseases are developed using DARPin technology. | |
| curevac.com | 2000 | Tubingen, Germany | $975.35M | 648 | mRNA-based therapeutics against cancer and infectious diseases are developed. | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. | |
| ivericbio.com | 2007 | New York, United States | $206.77M | 94 | Gene therapy solutions for retinal diseases are developed. | |
| gensight-biologics.com | 2011 | Paris, France | $76.63M | – | Viral vector-based gene therapies for retinal diseases are developed. |
Detailed competitors of 4DMT
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of 4DMT
The website of 4DMT (4dmoleculartherapeutics.com) receives about 9.3K visits a month and ranks #2,455,177 among all websites worldwide, #3,363 in Biotechnology and Pharmaceuticals.
- Monthly visits9.3K
▲ 4.7% vs previous month
- Unique visitors4.1K
per month
- Global rank#2,455,177
among all websites
- Category rank#3,363
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit33 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with 4DMT. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sierraeyeassociates.com | sierraeyeassociates.com | 100% | – | #5,889,007 | – |
Latest news on 4Dmt
Complete news archive for 4DMT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to 4DMT
10 companies that operate in the same segment as 4DMT (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 4DMT
4DMT was founded in 2013 and raised its 1st funding round 2 years after it was founded.
4DMT is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
4DMT is a funded company, having raised a total of $186.59M across 6 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on Aug 2015.
4DMT has 227 employees.
Annual revenue of 4DMT is $85.21M as on Dec 31, 2025.
Genetic medicines are innovated by 4DMT using a proprietary vector platform for large market diseases. Focus is placed on ophthalmology, pulmonology, and cardiology sectors. Customized vectors are optimized for specific diseases, aiming for curative intent. Partnerships with patient organizations are maintained to address unmet needs. Continuous improvement of products is pursued to benefit patients significantly.
4DMT's top competitors include MeiraGTx, EyePoint Pharmaceuticals and Rezolute.
4DMT offers 4D-150 and 4D-710.
Yes, 4DMT is publicly traded on NASDAQ under the ticker symbol FDMT.
4DMT has 20 investors. Key investors include Pfizer, Mirae Asset, Janus Henderson Investors, Cystic Fibrosis Foundation, and Perceptive Advisors.
4DMT operates through 4D Molecular Therapeutics.